Search research articles
Contact Us
Filters
Showing results (11-20 of 41) with videos related to
Page
of 5
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 24, 2006
Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo
Francesca Bruzzese, Elena Di Gennaro, Antonio Avallone, et al.
Cancer Biology & Therapy
|
March 10, 2009
Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed
Elena Di Gennaro, Francesca Bruzzese, Stefano Pepe, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|
August 3, 2025
Drug-like molecules targeting androgen receptor's allosteric binding sites selected by augmented AI and high-throughput screening as antitumor agents against prostate cancer
Francesca Bruzzese, Federica Iannelli, Maria Serena Roca, et al.
Anti-Cancer Drugs
|
June 22, 2007
Synergistic antitumour effect of raltitrexed and 5-fluorouracil plus folinic acid combination in human cancer cells
Antonio Avallone, Elena Di Gennaro, Francesca Bruzzese, et al.
Oncotarget
|
December 8, 2014
Proteomic analysis of zoledronic-acid resistant prostate cancer cells unveils novel pathways characterizing an invasive phenotype
Maria Rita Milone, Biagio Pucci, Katia Bifulco, et al.
Cancer Cell International
|
November 16, 2024
Integrated proteomics and metabolomics analyses reveal new insights into the antitumor effects of valproic acid plus simvastatin combination in a prostate cancer xenograft model associated with downmodulation of YAP/TAZ signaling
Federica Iannelli, Rita Lombardi, Susan Costantini, et al.
Oncotarget
|
August 28, 2015
Annexin A1 is involved in the acquisition and maintenance of a stem cell-like/aggressive phenotype in prostate cancer cells with acquired resistance to zoledronic acid
Valentina Bizzarro, Raffaella Belvedere, Maria Rita Milone, et al.
Molecular Cancer Therapeutics
|
June 14, 2019
Vorinostat Potentiates 5-Fluorouracil/Cisplatin Combination by Inhibiting Chemotherapy-Induced EGFR Nuclear Translocation and Increasing Cisplatin Uptake
Geny Piro, Maria Serena Roca, Francesca Bruzzese, et al.
Journal of Medicinal Chemistry
|
August 29, 2024
Harnessing Nitric Oxide-Donating Benzofuroxans for Targeted Inhibition of Carbonic Anhydrase IX in Cancer
Silvia Bua, Alessio Nocentini, Alessandro Bonardi, et al.
Free Radical Biology & Medicine
|
September 28, 2015
Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway
Alessandra Leone, Maria Serena Roca, Chiara Ciardiello, et al.
Page
of 5
Search research articles
Search
Showing results (11-20 of 41) with videos related to
Sort By:
Page
of 5
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 24, 2006
Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo
Francesca Bruzzese, Elena Di Gennaro, Antonio Avallone, et al.
Cancer Biology & Therapy
|
March 10, 2009
Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed
Elena Di Gennaro, Francesca Bruzzese, Stefano Pepe, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|
August 3, 2025
Drug-like molecules targeting androgen receptor's allosteric binding sites selected by augmented AI and high-throughput screening as antitumor agents against prostate cancer
Francesca Bruzzese, Federica Iannelli, Maria Serena Roca, et al.
Anti-Cancer Drugs
|
June 22, 2007
Synergistic antitumour effect of raltitrexed and 5-fluorouracil plus folinic acid combination in human cancer cells
Antonio Avallone, Elena Di Gennaro, Francesca Bruzzese, et al.
Oncotarget
|
December 8, 2014
Proteomic analysis of zoledronic-acid resistant prostate cancer cells unveils novel pathways characterizing an invasive phenotype
Maria Rita Milone, Biagio Pucci, Katia Bifulco, et al.
Cancer Cell International
|
November 16, 2024
Integrated proteomics and metabolomics analyses reveal new insights into the antitumor effects of valproic acid plus simvastatin combination in a prostate cancer xenograft model associated with downmodulation of YAP/TAZ signaling
Federica Iannelli, Rita Lombardi, Susan Costantini, et al.
Oncotarget
|
August 28, 2015
Annexin A1 is involved in the acquisition and maintenance of a stem cell-like/aggressive phenotype in prostate cancer cells with acquired resistance to zoledronic acid
Valentina Bizzarro, Raffaella Belvedere, Maria Rita Milone, et al.
Molecular Cancer Therapeutics
|
June 14, 2019
Vorinostat Potentiates 5-Fluorouracil/Cisplatin Combination by Inhibiting Chemotherapy-Induced EGFR Nuclear Translocation and Increasing Cisplatin Uptake
Geny Piro, Maria Serena Roca, Francesca Bruzzese, et al.
Journal of Medicinal Chemistry
|
August 29, 2024
Harnessing Nitric Oxide-Donating Benzofuroxans for Targeted Inhibition of Carbonic Anhydrase IX in Cancer
Silvia Bua, Alessio Nocentini, Alessandro Bonardi, et al.
Free Radical Biology & Medicine
|
September 28, 2015
Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway
Alessandra Leone, Maria Serena Roca, Chiara Ciardiello, et al.
Page
of 5